VIDAZA (Celgene Corporation)


Welcome to the PulseAid listing for the VIDAZA drug offered from Celgene Corporation. This Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Celgene Corporation
NON-PROPRIETARY NAME: azacitidine
SUBSTANCE NAME: AZACITIDINE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC]
ROUTE: INTRAVENOUS; SUBCUTANEOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2004-07-05
END MARKETING DATE: 0000-00-00


VIDAZA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionVIDAZA from Celgene Corporation
LABELER NAME: Celgene Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 100(mg/1)
START MARKETING DATE: 2004-07-05
END MARKETING DATE: 0000-00-00
PRODUCT ID: 59572-102_2ee396fc-bd5b-444a-8f18-0760c6e7c4cf
PRODUCT NDC: 59572-102
APPLICATION NUMBER: NDA050794

Other AZACITIDINE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Actavis Pharma, Inc.Azacitidine
BluePoint LaboratoriesAzacitidine
Breckenridge Pharmaceutical, Inc.Azacitidine
Celgene CorporationVIDAZA
Dr. Reddy’s Laboratories Inc.Azacitidine
Fresenius Kabi USA, LLCAzacitidine
Mylan Institutional LLCAzacitidine
Sandoz IncAzacitidine
Seton PharmaceuticalsAZACITIDINE
Shilpa Medicare LimitedAZACITIDINE
Wockhardt USA LLC.AZACITIDINE